PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34936871-3 2021 Using single-cell RNA-sequencing to perform an unbiased assessment of the cellular landscape of human prostate, we identify a subset of tumor-enriched androgen receptor-negative luminal epithelial cells with increased expression of cancer-associated genes. Phenobarbital 178-185 androgen receptor Homo sapiens 151-168 34973338-5 2022 Interestingly, we found that TRIB2 downregulates the luminal markers AR (androgen receptor) and CK8 (cytokeratin 8) in prostate cancer cells but upregulates the neuronal transcription factor BRN2 (Brain-2) and the stemness factor SOX2 (SRY-box 2) to induce neuroendocrine characteristics. Phenobarbital 53-60 androgen receptor Homo sapiens 69-71 34973338-5 2022 Interestingly, we found that TRIB2 downregulates the luminal markers AR (androgen receptor) and CK8 (cytokeratin 8) in prostate cancer cells but upregulates the neuronal transcription factor BRN2 (Brain-2) and the stemness factor SOX2 (SRY-box 2) to induce neuroendocrine characteristics. Phenobarbital 53-60 androgen receptor Homo sapiens 73-90 35562350-3 2022 We demonstrate that MYC overexpression significantly diminishes the androgen receptor (AR) transcriptional program (the set of genes directly targeted by the AR protein) in luminal prostate cells without altering AR expression. Phenobarbital 173-180 androgen receptor Homo sapiens 68-85 34121071-1 2021 BACKGROUND: Androgen receptor (AR) expression is a potential therapeutic target in breast cancer (BC) as it is frequently expressed in the luminal A and B subtypes and in approximately one third of basal-like cancers. Phenobarbital 139-146 androgen receptor Homo sapiens 12-29 34121071-1 2021 BACKGROUND: Androgen receptor (AR) expression is a potential therapeutic target in breast cancer (BC) as it is frequently expressed in the luminal A and B subtypes and in approximately one third of basal-like cancers. Phenobarbital 139-146 androgen receptor Homo sapiens 31-33 34121071-11 2021 CONCLUSION: AR is expressed in more than one third of BC BM with the highest rates among the luminal/HER2-negative BC subtype and may therefore be a potential prognostic and predictive biomarker in this particular BC population. Phenobarbital 93-100 androgen receptor Homo sapiens 12-14 35562350-3 2022 We demonstrate that MYC overexpression significantly diminishes the androgen receptor (AR) transcriptional program (the set of genes directly targeted by the AR protein) in luminal prostate cells without altering AR expression. Phenobarbital 173-180 androgen receptor Homo sapiens 87-89 35562350-3 2022 We demonstrate that MYC overexpression significantly diminishes the androgen receptor (AR) transcriptional program (the set of genes directly targeted by the AR protein) in luminal prostate cells without altering AR expression. Phenobarbital 173-180 androgen receptor Homo sapiens 158-160 35079116-6 2022 RESULTS: The Luminal subtype of mCRPCs has higher Androgen Receptor (AR) expression and copy number alterations as compared with the other subtypes. Phenobarbital 13-20 androgen receptor Homo sapiens 50-67 35227076-1 2022 Purpose: The authors aimed to evaluate the prognostic and predictive value of androgen receptor (AR) expression in patients with luminal/human EGFR2 negative (HER2-) T1N0 breast cancer. Phenobarbital 129-136 androgen receptor Homo sapiens 78-95 35227076-1 2022 Purpose: The authors aimed to evaluate the prognostic and predictive value of androgen receptor (AR) expression in patients with luminal/human EGFR2 negative (HER2-) T1N0 breast cancer. Phenobarbital 129-136 androgen receptor Homo sapiens 97-99 35203681-11 2022 The appearance of AR mRNA and additional luminal marker gene expression changes following proteasome inhibition suggests control of essential cofactor(s) of AR mRNA expression and luminal differentiation at this proteolytic level. Phenobarbital 41-48 androgen receptor Homo sapiens 157-159 35079116-6 2022 RESULTS: The Luminal subtype of mCRPCs has higher Androgen Receptor (AR) expression and copy number alterations as compared with the other subtypes. Phenobarbital 13-20 androgen receptor Homo sapiens 69-71 33753865-11 2021 Our findings highlight that TN-ILC is a unique aggressive breast cancer associated with elderly age, which belong to the luminal androgen receptor subtype as determined by immunohistochemistry and transcriptomic profiling. Phenobarbital 121-128 androgen receptor Homo sapiens 129-146 32742928-10 2020 Furthermore, AR is enriched in the luminal papillary mRNA subtype of urothelial carcinoma and also mediates resistance to cisplatin-based chemotherapy. Phenobarbital 35-42 androgen receptor Homo sapiens 13-15 32619596-9 2020 The androgen receptor activity signature demonstrated a dramatic difference between basal (0.19) and luminal (0.62) subtypes (p<0.001). Phenobarbital 101-108 androgen receptor Homo sapiens 4-21 32982642-6 2020 Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Phenobarbital 130-137 androgen receptor Homo sapiens 82-99 32982642-6 2020 Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Phenobarbital 130-137 androgen receptor Homo sapiens 101-103 32982642-6 2020 Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Phenobarbital 130-137 androgen receptor Homo sapiens 138-140 32697770-10 2020 The observed molecular apocrine differentiation implicates that triple-negative PLC can be categorized into the luminal AR subtype. Phenobarbital 112-119 androgen receptor Homo sapiens 120-122 32373367-10 2020 Thus, the expression levels of AR, miR-185, miR-205, and miR-21 can serve as markers to predict cancer spread to the lymph node in luminal B- and HER2-positive subtypes of breast cancer. Phenobarbital 131-138 androgen receptor Homo sapiens 31-33 32510949-2 2020 Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer. Phenobarbital 74-81 androgen receptor Homo sapiens 82-99 32181676-4 2020 The low expression level of AR is strongly associated with poor recurrence-free survival, especially with poor distance metastasis-free survival in luminal A patients, but inverse in HER2 (human epidermal growth factor receptor-2) enriched patients. Phenobarbital 148-155 androgen receptor Homo sapiens 28-30 31801883-5 2019 CXCR2-driven NE cells were critical for the tumor microenvironment by providing a survival niche for the AR+ luminal cells. Phenobarbital 109-116 androgen receptor Homo sapiens 105-107 31888566-2 2019 Transcriptome studies showed that TNBCs are a heterogeneous group that includes a potentially hormone-dependent subtype named luminal-AR. Phenobarbital 126-133 androgen receptor Homo sapiens 134-136 31888566-10 2019 CONCLUSIONS: We identified an AR+ FOXA1+ CK14- subgroup of triple-negative FMCs that might correspond to the luminal-AR subgroup of human triple-negative breast cancers. Phenobarbital 109-116 androgen receptor Homo sapiens 30-32 31888566-10 2019 CONCLUSIONS: We identified an AR+ FOXA1+ CK14- subgroup of triple-negative FMCs that might correspond to the luminal-AR subgroup of human triple-negative breast cancers. Phenobarbital 109-116 androgen receptor Homo sapiens 117-119